# NEPRA FOODS INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (AMENDED AND RESTATED) FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020 (EXPRESSED IN CANADIAN DOLLARS) (Unaudited)

#### **NOTICE TO READER:**

The attached unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2021, together with the accompanying notes hereto, and originally filed on November 29, 2021 are hereby amended and restated (the "Amended and Restated Financial Statements"). The Amended and Restated Financial Statements have been updated for the following items collectively referred to as "the Amendments". The Condensed Consolidated Statement of Cashflow and Note 15 have been amended and restated to correct the presentation of lease payments and cash interest paid. Disclosure of convertible notes' and lease liability's contractual cashflows under Note 18 have been amended and restated. Note 19 has been updated for additional subsequent events to the filing date hereof. The effect of the Amendments does not impact the Company's ongoing operations or cash position. Further detail regarding the Amendments can be seen in Note 20 of the Amended and Restated Financial Statements

Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian Dollars) (Unaudited)

As at	Notes	September 30, 2021	December 31, 2020
ASSETS			
Current assets			
Cash		\$ 4,279,483	\$ 492,976
Accounts and other receivables	5, 18	519,848	142,861
Prepaid expenses and deposits	14	798,328	97,859
Inventory	6	1,501,679	535,490
Due from related party	11, 14	9,427	8,689
· ·		7,108,765	1,277,875
Long-term deposit	8	105,046	148,340
Property and equipment	7, 14	262,671	63,696
Right-of-use assets	8	2,365,271	22,958
Total assets		\$ 9,841,753	\$ 1,512,869
LIABILITIES AND SHAREHOLDERS' DE Current liabilities	FICIENCY		
Accounts payable and accrued liabilities	10, 14	\$ 1,060,845	\$ 525,596
Loan payable – current portion	11	15,154	14,488
Lease liability – current portion	9, 14	90,183	13,927
Promissory note payable	14	203,353	203,888
Convertible notes	12	456,083	844,632
		1,825,618	1,602,531
Lease liability	9, 14	2,480,330	12,714
Loans payable	11, 14	183,958	197,338
Total liabilities		4,489,906	1,812,583
Shareholders' deficiency			
Share capital	13, 14	9,313,441	829,358
Reserves		371,886	
Accumulated other comprehensive income		(34,230)	5,160
Deficit		(4,299,250)	(1,134,232)
Total shareholders' deficiency		5,351,847	(299,714)
Total liabilities and shareholders' deficiency		\$ 9,841,753	\$ 1,512,869
Nature of operations and going concern (Note 1) Subsequent events (Note 19) Approved on behalf of the Board on March 9			
	irector		

The accompanying notes are an integral part of these condensed consolidated interim financial statements

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss For the three and nine months ended September 30 (Expressed in Canadian Dollars) (Unaudited)

			For the three mo Septembe		For the nine n Septem	
	Notes		2021	2020	2021	2020
Revenue						
Sales	17	\$	1,201,530	667,876	4,262,350	1,759,370
Consulting		Ψ	411	23,323	130,089	73,803
consuming			1,201,941	691,199	4,392,439	1,833,173
Cost of sales	5, 6, 7		1,048,201	525,996	3,615,052	1,413,338
		\$	153,740	165,203	777,387	419,835
Expenses						
Accretion	11		363	40	1,080	474
Amortization	7,8		63,807	14,547	186,893	15,418
Bad debts	.,.		16,672	-	16,672	
Consulting			471,948	1,553	529,989	5,489
General and administrative			248,358	4,582	550,066	20,559
Interest expense			106,158	19,295	316,410	39,399
Professional fees	14		106,573	(1,260)	577,246	
Research and development			21,638	1,491	82,475	16,364
Salaries and benefits	14		397,704	94,094	1,287,628	250,779
Share-based payments			119,965	-	119,965	
Travel			24,904	32,808	57,421	46,114
			,	,	,	,
Net income (loss) before other items		\$	(1,424,350)	(1,947)	(2,948,458)	25,239
		Ŧ	(1,12,,000)	(1,2.17)	(2,) 10, 100)	20,203
Other items					05 101	
Foreign exchange	0		20,581	-	25,101	-
Interest income	8		2,559	-	7,451	-
Change in fair value of convertible	10		(107, 120)		(172,002)	
debt	12		(197,129)	-	(173,092)	-
Loss on conversion of debt	12		(24,113)	9,478	(24,113)	54,047
Government assistance	11 16		-	9,470	(51,907)	54,047
Transaction expense	10	\$	- (1 622 452)	7,531	(3,165,018)	79,286
Net income (loss)		Þ	(1,622,452)	7,551	(3,103,010)	19,200
Other comprehensive income (items						
that may be reclassified to profit						
or loss) Exchange difference on translation						
between presentation and functional						
currencies			(45,746)	11,543	(39,390)	(16,703)
Comprehensive income (loss)		\$	(1,668,198)	19,047	(3,204,408)	62,583
Income (loss) per share, basic and				·		·
diluted		\$	(0.09)	0.01	(0.26)	0.06
Weighted average number of shares		*	(0.02)		(0.20)	0.00
outstanding, basic and diluted			17,886,837	1,344,355	12,381,375	1,228,729

The accompanying notes are an integral part of these condensed consolidated interim financial statements

Condensed Consolidated Interim Statements of Cash Flows For the nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

	2021	2020
Operating activities		
Net (loss) income	\$ (3,165,018)	79,286
Adjustments for non-cash items		
Amortization	199,595	26,346
Accretion	1,080	474
Bad debt expense	16,672	
Interest	165,368	2,960
Government assistance	-	(54,047)
Change in fair value of convertible debt	173,093	-
Loss on conversion of debt	24,113	-
Transaction expense	51,907	-
Foreign exchange	(7,832)	-
Share-based payments	119,965	-
Changes in non-cash working capital items:		
Accounts receivable	(389,126)	(72,315)
Prepaid expenses and deposits	(709,164)	(3,496)
Inventory	(941,962)	(108,775)
Accounts payable and accrued liabilities	505,398	52,120
Due to related party	(751)	-
Net cash used in operating activities	(3,956,662)	(77,447)
Investing activity		
Purchase of equipment	(218,914)	-
Cash acquired in reverse takeover	251	-
Net cash used in investing activity	(218,663)	-
Financing activities		
Proceeds from issuance of shares	443,642	_
Net IPO proceeds	6,517,059	_
Repayment of lease liability		(21,335)
Proceeds from SBA loan	_	208,839
Loan repayments	(16,957)	200,009
Proceeds from convertible debt	1,068,295	-
Advances to a related party	-	(50,431)
Net cash provided by financing activities	8,012,039	137,073
Change in cash	3,836,714	59,626
Effect of change in foreign exchange rates on cash	(50,208)	(18,946)
Cash, beginning	492,977	17,463
Cash, ending	\$ 4,279,483	58,143

Supplemental Disclosure with Respect to Cash Flows (Note 15)

Condensed Consolidated Interim Statements of Changes in Shareholders' Deficiency For the nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars)

(Unaudited)

		Share ca	pital		Reserves		Accumulated other comprehensive income		Deficit		Total shareholders'
	Common Shares*	Class A Shares*		Amount			(loss)				deficiency
Balance, December 31, 2019	1,073,653	96,629	\$	1	\$ -	\$	2,638	\$	(592,210)	\$	(589,571)
Units issued for settlement of debt	161,455	14,531		66,827	-		-		-		66,827
Currency translation adjustment	-	-		-	-		(16,703)		-		(16,703)
Net income	-	-		-	-		-		79,286		79,286
Balance, September 30, 2020	1,235,108	111,160	\$	66,827	\$ -	\$	(14,065)	\$	(512,924)	\$	(460,161)
Balance, December 31, 2020	3,655,711	273,468	\$	829,358	\$ -	\$	5,160	\$	(1,134,232)	\$	(299,714)
Shares issued for settlement of	5,055,711	275,400	Ŧ	027,550		Ŧ	-,	Ŷ	(1,10,1,101)	Ŧ	()
debt	997,426	-		39,361	\$ -		-		-		39,361
Shares issued in private											
placement	9,999,971	-		443,642	-		-		-		443,642
Reverse takeover	100	-		251	-		-		-		251
Shares issued pursuant to IPO	15,903,465	-		5,966,153	251,921		-		-		6,218,074
Finder's shares	636,138	-		298,985	-		-		-		298,985
Debt conversion	4,409,231	-		1,735,691	-		-		-		1,735,691
Share-based payments	-	-		-	119,965		-		-		119,965
Currency translation adjustment	-	-		-	-		(39,390)		-		(39,390)
Net loss	-	-		-	-		-		(3,165,018)		(3,165,018)
Balance, September 30, 2021	35,602,042	273,468	\$	9,313,441	371,886	\$	(34,230)	\$	4,299,250	\$	5,351,847

\* The number of shares outstanding before the RTO have been restated to reflect the effect of issuing 0.873288 RTO share for each share outstanding.

The accompanying notes are an integral part of these condensed consolidated interim financial statements

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 1. Nature of Operations and Going Concern

Nepra Foods Inc. ("Nepra" or the "Company") was incorporated on November 27, 2020 under the provisions of the under the British Columbia Business Corporations Act. The Company operates as a vertically integrated healthy plant-based food and speciality ingredient company supporting allergen free and functional food brands. The Company's head office is located at 7025 S. Revere Parkway, Unit 100, Centennial, Colorado, USA 80112. The Company's registered and records office is located at Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Canada, V6E 4N7.

On April 16, 2021, the Company completed the reverse take over ("RTO") of Nepra Foods, Ltd. ("Nepra US"). Nepra US was incorporated as a limited liability company ("LLC") on August 15, 2019 under the provisions of the Colorado Revised Status and on November 1, 2020, Nepra US converted from a LLC to a corporation. These condensed consolidated interim financial statements are presented as a continuation of Nepra US as the deemed acquirer (Note 16).

These condensed consolidated interim financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. During the nine months ended September 30, 2021, the Company had negative cash flows from operations of \$3,841,320 and as at September 30, 2021, had an accumulated deficit of \$4,299,250. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue its operations and to realize assets at their carrying values is dependent upon its ability to raise financing and generate profits and positive cash flows from operations in order to cover its operating costs. From time to time, the Company generates working capital to fund its operations by raising additional capital through equity or debt financing. However, there is no assurance it will be able to continue to do so in the future. These condensed consolidated interim financial statements do not give effect to any adjustments required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying condensed consolidated interim financial statements.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 2. Basis of Presentation, Functional Currency, and Basis of Combination and Consolidation

#### **Statement of Compliance**

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 *Interim Financial Reporting*. They do not include all the information required for a complete set of financial statements prepared in accordance with International Financial Reporting Standards (IFRSs). As such, they must be read in conjunction with the annual audited consolidated financial statements for the period ended December 31, 2020 and the notes thereto. However, selected notes are included that are significant to understanding the Company's financial position and performance since the last annual consolidated financial statements are presented in Canadian dollars. The Company's functional currency is the US dollar. The amounts in the tables are expressed in Canadian dollars, unless otherwise stated.

These condensed consolidated interim financial statements were authorized for issue by the Board of Directors on March 9, 2022.

These condensed consolidated interim financial statements have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit and loss, which are stated at their fair value. In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

These condensed consolidated interim financial statements incorporate the accounts of the Company and its controlled subsidiaries from the date of acquisition. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The Company's wholly owned subsidiaries include: Nepra Foods, Ltd., incorporated August 15, 2019, Gluten Free Baking Solutions, LLC ("GFBS"), incorporated on August 10, 2016, and Total Blending Solutions, Ltd. ("TBS"), incorporated on November 25, 2019.

## 3. Significant Accounting Policies

The significant accounting policies applied in the preparation of these condensed consolidated interim financial statements are consistent with the accounting policies disclosed in Note 3 of the audited financial statements for the year ended December 31, 2020. These condensed consolidated interim statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2020.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 3. Significant Accounting Policies (cont'd)

#### **Share-based payments**

Equity-settled share-based payments to employees are measured at the fair value of the instruments at the grant date and recognized in expense over the vesting periods. Equity-settled share-based payments to nonemployees are measured at the fair value of goods or services received or the fair value of the equity instruments issued if it is determined that the fair value of the goods or services received cannot be reliably measured. Nonemployee share-based payments are recognized in expense at the date the goods or services are received. The corresponding amount is recorded to reserves. Upon the exercise of stock options, consideration received on the exercise is recorded as share capital and the related amount in reserves is transferred to share capital.

#### Accounting standards issued but not yet effective

Other accounting standards or amendments to existing accounting standards that have been issued but have future effective dates are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

#### 4. Critical Accounting Estimates and Judgements

In preparing these condensed consolidated interim financial statements, management has made judgments, estimates and assumptions that affect the applicable of the Company's accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. In preparing these condensed consolidated interim financial statements, the significant estimates and critical judgments were the same as those applied to the financial statements as at and for the year ended December 31, 2020.

#### 5. Accounts receivable

	September 30, 2021	December 31, 2020
GST/HST receivable	\$ 61,776	\$ 144,871
Trade receivables	476,914	-
Expected credit losses	(18,842)	(2,010)
Net accounts receivable	\$ 519,848	\$ 142,861

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

# 6. Inventory

Inventory consists primarily of raw materials and finished goods.

	September 30,	
	2021	December 31, 2020
Raw materials	\$ 180,732	\$ 101,335
Work-in-progress	61,220	16,251
Finished goods	1,259,727	417,904
	\$ 1,501,679	\$ 535,490

# 7. Property and Equipment

	Furniture and equipment			Leasehold improvements	Total
Cost					
Balance, December 31, 2019	\$ 8,474	\$ -	\$	-	\$ 8,474
Additions	-	62,679		-	62,679
Foreign exchange adjustment	(336)	-		-	(336)
Balance, December 31, 2020	\$ 8,138	\$ 62,679	\$	-	\$ 70,817
Additions	87,253	89,652		42,009	218,914
Foreign exchange adjustment	1,358	1,252		663	3,273
Balance, September 30, 2021	\$ 96,749	\$ 153,583	\$	42,672	\$ 293,004

	]	Furniture and equipment	Warehouse equipment		Leasehold improvements		Total
Accumulated Amortization							
Balance, December 31, 2019	\$	3,486	\$	-	\$ -	\$	3,486
Amortization		1,712		2,354	-		4,066
Foreign exchange adjustment		(316)		(115)	-		(431)
Balance, December 31, 2020	\$	4,882	\$	2,239	\$ -	\$	7,121
Amortization		5,453		14,065	3,351		22,869
Foreign exchange adjustment		74		216	53		343
Balance, September 30, 2021	\$	10,409		16,520	3,404		30,333
Net Book Value							
At December 31, 2020	\$	3,256	\$	60,440	\$ -	\$	63,696
At September 30, 2021	\$	86,340	\$	137,063	\$ 39,268	\$	262,671

Amortization of equipment used in production is included in the cost of inventory. During the nine months ended September 30, 2021, amortization of \$14,064 (2020 - \$Nil) was included in the cost of inventory.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

## 8. Right-of-use Assets

#### Equipment

On October 16, 2017, the Company entered into an equipment lease agreement. The lease term commenced November 1, 2017 and ends on October 1, 2022. The Company is committed to paying a monthly rental fee of USD\$1,044 (CAD\$1,395) to a related party (Note 14).

#### Building

The Company entered into a lease agreement for the building located at 7025 South Revere Parkway, Ste. 100, Centennial, Colorado 80112. The lease includes annual step-up payments and commences January 1, 2021 and expires on June 30, 2031. In connection with the lease agreement, the Company paid a security deposit of \$146,592 (USD\$116,409), to be repaid as follows: \$97,728 (USD\$77,606) after 24 months and \$48,864 (USD\$38,803) upon completion of the lease. The deposit has been discounted using an incremental borrowing rate of 10% per annum.

A reconciliation of the long-term deposit is as follows:

At December 31, 2020	\$ 148,340
Adjustment to fair value	(50,001)
Interest income	7,442
Foreign exchange adjustment	(735)
At September 30, 2021	\$ 105,046

The Company's right-of-use asset consists of a lease for equipment and a lease for a building.

Right-of-use asset	Equipment	Building	Total
At December 31, 2019	\$ 36,246	\$ -	\$ 36,246
Additions	-	231,975	231,975
Amortization expense	(13,170)	(27,106)	(40,276)
Derecognition	-	(206,200)	(206,200)
Foreign exchange adjustment	(118)	1,331	1,213
At December 31, 2020	\$ 22,958	\$ -	\$ 22,958
Additions	-	2,509,395	2,509,395
Amortization expense	(9,222)	(178,089)	(187,311)
Foreign exchange adjustment	(205)	20,434	20,229
At September 30, 2021	\$ 13,531	\$ 2,351,740	\$ 2,365,271

A portion of the amortization of equipment and building right-of-use assets is included in the cost of inventory. During the nine months ended September 30, 2021, amortization of \$9,222 (2020 - \$Nil) was included in the cost of inventory

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 9. Leases

The lease liabilities of the equipment and the building have been calculated using an incremental borrowing rate of 10% per annum. The Company's total payments for its leases were 115,342 in 2021 (2020 - 8,546).

The Company's lease liability is as follows:

	September 30,	December 31,
Lease liability	2021	2020
Current portion	\$ 90,183	\$ 13,927
Long-term portion	2,480,330	12,714
Total lease liability	\$ 2,570,513	\$ 26,641

The consolidated statement of loss and comprehensive loss shows the following amounts relating to leases:

	September 30,	September 30,
	2021	2020
Amortization charge of equipment right-of-use assets	\$ 9,222	\$ 9,972
Amortization charge of building right-of-use assets	178,089	-
Interest expense	187,899	2,799
	\$ 375,210	\$ 12,771

The Company is committed to minimum lease payments as follows:

	 September 30,	December 31,	
Maturity analysis	2021	2020	
Less than one year	\$ 313,160	\$ 15,964	
One year to five years	1,614,233	13,303	
More than five years	2,184,314	-	
Total undiscounted lease liabilities	\$ 4,111,707	\$ 29,267	

#### **10. Accounts Payable and Accrued Liabilities**

	September 30,	December 31,
	2021	2020
Trade payables	\$ 827,382	\$ 462,518
Accrued liabilities	233,463	63,078
	\$ 1,060,845	\$ 525,596

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 11. Loans Payable

a) On May 16, 2020 ("date of advance"), GFBS received a loan for gross proceeds of \$210,330 (USD \$150,000) from the U.S. Small Business Administration under the Economic Injury Disaster Loan program. The loan bears annual interest at a rate of 3.75%. Monthly repayments of \$996 (USD \$731) commence 12 months from the date of advance and will be applied first to interest, then to principal and the loan matures 30 years from the date of advance. The benefit of the government loan received at below market rate of interest is treated as a government grant. The loan was recognized at fair value using the Company's estimated incremental borrowing rate of 10%, which resulted in a fair value of \$140,887. The difference between the initial carrying amount and proceeds received is the value of the government assistance of \$54,047. The Company received an additional USD\$3,000 (CAD\$4,206) for total proceeds of USD\$153,000 (CAD\$214,536). As at September 30, 2021, accrued interest of \$9,532 (USD \$7,500) is recorded in accounts payable and accrued liabilities.

The loan is secured by all tangible and intangible property of the borrower as at the agreement date and any property acquired by the borrower after the agreement date.

Balance, December 31, 2019	\$ 
Principal balance	210,330
Assistance on adjustment to fair value	(54,047)
Foreign exchange adjustment	(15,396)
	140,887
Accretion expense	704
Additional funds received	4,206
Foreign exchange adjustment	(1,680)
Balance, December 31, 2020	\$ 144,117
Accretion	1,080
Foreign exchange adjustment	(361)
Balance, September 30, 2021	\$ 144,836

The balance outstanding at September 30, 2021 is as follows:

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 11. Loans Payable (cont'd)

b) On September 15, 2020, the Company, through its subsidiary GFBS, entered into a financing agreement for equipment purchased for USD \$49,187 (CAD \$62,679). The loan commenced on September 15, 2020, has an effective interest rate of 9.91%, and matures on August 15, 2024. The Company is required to make monthly payments of USD\$1,215 (CAD \$1,623) and the balance of the loan is due on maturity.

Balance, December 31, 2019	\$ -
Loan proceeds	62,679
Loan repayments	(4,883)
Interest	1,564
Foreign exchange adjustment	164
Balance, December 31, 2020	\$ 59,524
Loan repayments	(14,472)
Interest	3,911
Foreign exchange adjustment	(326)
Total loan balance	48,637
Less current portion	(15,154)
Non-current balance, September 30, 2021	\$ 33,483

The loan is secured by the equipment purchased with the proceeds of the loan. See also Note 14.

c) On July 1, 2020, the Company entered into an unsecured revolving loan facility with a related party for up to \$200,000 USD. The outstanding balance, if any, on the revolving loan is due on or before December 31, 2025. The facility bears interest of 6% per annum. The balance due on this facility as of September 30, 2021 was \$5,639 (2020 - \$8,185). See Note 14.

#### **12.** Convertible Notes

On March 3, 2021, Nepra Foods, Ltd. closed the second tranche of the Series I convertible note financing and issued US\$341,000 (CAD\$439,396) of convertible notes bearing interest at 8% annually. The convertible notes mature on March 3, 2023 and are secured by a floating charge on all assets of the Company. If the Company completes a listing of the Company's common shares on a stock exchange in Canada or the United States, the principal and interest shall automatically be converted into common shares of the parent at a price equal to the greater of 80% of the issuance price under the Qualified Public Offering or CAD \$0.10. No fractional shares will be issued, and any fractional shares will be rounded down to the nearest whole number.

On April 2, 2021, Nepra Foods, Ltd. closed the Series II convertible note financing and issued US\$295,000 (CAD\$380,123) of convertible notes bearing interest at 8% annually. The convertible notes mature on April 2, 2023 and are secured by a floating charge on all assets of the Company. If the Company completes a listing of the Company's common shares on a stock exchange in Canada or the United States, the principal and interest shall automatically be converted into common shares of the parent at a price equal to the greater of the issuance price under the Qualified Public Offering or CAD \$0.10. No fractional shares will be issued, and any fractional shares will be rounded down to the nearest whole number. The Company has elected to measure the instruments at fair value through profit or loss (FVTPL). On inception, the fair value of the instruments were determined to be for the transaction amounts.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### **12.** Convertible Notes (cont'd)

On June 11, 2021, the Company closed the Series III convertible note financing and issued CAD\$230,000 of convertible notes bearing interest at a rate of 9% annually and maturing on June 11, 2022. The convertible notes are secured by a floating charge on all assets of the Company. The principal amount of Series III Secured Notes, plus accrued and unpaid interest to the date of maturity, is convertible, in whole or in part, at the option of the holder, at any time following 121 days after the issue date, but prior to the maturity date of such Series III Secured Notes, into common shares at the greater of the issuance price under the Qualified Public Offering or CAD \$0.10. No fractional shares will be issued and any fractional shares will be rounded down to the nearest whole number. At any time following 121 days after the issue date, but prior to the date that is ten (10) days immediately preceding the maturity date of the Series III notes, if the common shares are trading on a stock exchange in Canada or the United States and the closing price of the common shares is equal to or greater than CAD\$0.60 for a period of ten (10) consecutive trading days, the Company can convert the principal amount plus accrued and unpaid interest to the date of maturity into common shares at the greater of the issuance price under the Qualified Public Offering or CAD \$0.10 by providing the holder not less than ten (10) days' prior written notice. The Company has elected to measure the instruments at fair value through profit or loss (FVTPL). On inception, the fair value of the instruments were determined to be for the transaction amounts.

On September 17, 2021, upon completion of the Company's initial public offering, the Series I convertible notes outstanding principal and interest of \$1,346,603 was automatically converted into 3,581,387 common shares of the Company at a price of \$0.376 per share. The Series I notes were accounted for at fair value through profit and loss in accordance with the Company's accounting policy. Upon conversion, the difference between the Series I convertible notes' fair value of \$1,327,983 and its outstanding principal plus interest resulted in a loss on conversion of debt of \$18,620 recognized in statement of loss and comprehensive loss.

On September 17, 2021, upon completion of the Company's initial public offering, the Series II convertible notes outstanding principal and interest of \$389,088 was automatically converted into 827,844 common shares of the Company at a price of \$0.47 per share. The Series II notes were accounted for at fair value through profit and loss in accordance with the Company's accounting policy. Upon conversion, the difference between the Series II convertible notes' fair value of \$383,595 and its outstanding principal plus interest resulted in a loss on conversion of debt of \$5,493 recognized in statement of loss and comprehensive loss.

As at September 30, 2021, the fair value of the Series III convertible notes increased as a result of the market price of the Company's common shares exceeding the conversion price per share of the Series III convertible notes. The increase in fair value of the Series III convertible notes was estimated using the Black-Scholes pricing model and the following assumptions: estimated volatility of 95.41%, risk free interest rate of 0.510%, expected life of 0.70 years, exercise price of \$0.47, a dividend yield of 0%, and a share price of \$0.76.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 12. Convertible Notes (cont'd)

Balance at December 31, 2019	\$ -
Proceeds	849,143
Interest	5,131
Foreign exchange adjustment	(9,642)
Balance at December 31, 2020	\$ 844,632
Proceeds	1,068,295
Interest	88,899
Change in fair value	173,092
Conversion of Series I and Series II debt	(1,711,578)
Foreign exchange adjustment	(7,257)
Balance at September 30, 2021	\$ 456,083

#### **13. Share Capital and Reserves**

On April 16, 2021, the Company completed the RTO of Nepra US. As the financial statements are considered a continuance of the operations of Nepra US and due to the reverse takeover, all of the share numbers and share prices in these financial statements have been adjusted, on a retroactive basis, to reflect this exchange.

#### Authorized capital

The Company is authorized to issue unlimited common shares and unlimited Class A common shares with no par value.

#### **Issued Capital**

During the nine months ended September 30, 2021:

- On February 24, 2021, the Company issued 997,426 common shares to settle outstanding debt of US\$30,888 (CAD\$39,361).
- On March 5, 2021, the Company closed a private placement and issued 9,999,971 common shares for proceeds of US\$350,000 (CAD\$443,642).
- On April 16, 2021, 100 common shares were issued in connection with the RTO between the Company and Nepra US (Note 16).
- On September 17, 2021, the Company completed its initial public offering of 15,903,465 shares at a price of \$0.47 per share for gross proceeds of \$7,474,629. The Company incurred share issuance costs of \$957,570 in cash, issued 636,138 common shares finder's fees valued at \$298,985, and issued 898,889 finder's warrants valued at \$251,921 using the Black Scholes pricing model. Each warrant is exercisable into one common share at an exercise price of \$0.47 until expiry on September 17, 2023.
- On September 17, 2021, the Company issued 3,581,387 shares at a price of \$0.376 per share upon conversion of the Series I convertible notes (Note 12).
- On September 17, 2021, the Company issued 827,844 shares at a price of \$0.47 per share upon conversion of the Series II convertible notes (Note 12).

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 13. Share Capital and Reserves (cont'd)

#### During the nine months ended September 30, 2020:

- On June 30, 2020, the Company completed a reorganization whereby the Company issued 1,073,653 common shares and 96,629 Class A shares to the members of GFBS and GFSM, in exchange for all their membership units in GFBS and GFSM, resulting in GFBS and GFSM becoming wholly owned subsidiaries of Nepra.
- On July 1, 2020, 161,455 common shares and 14,531 Class A shares membership units of Nepra were issued to settle outstanding debt of US\$50,000 (CAD\$66,827).

## **Stock Options**

#### Stock Option Plan

The Stock Option Plan was adopted by the Company's board of directors on April 16, 2021. The aggregate number of common shares which are reserved for issuance under the Stock Option Plan may not exceed 11,789,310. The exercise price of any stock options granted under the Option Plan shall be determined by the Compensation Committee of the Board, but may not be less than the greater of the closing market price of the Common Shares on (a) the trading day prior to the date of grant of the stock options; and (b) the date of grant of the stock options. The term of any stock option under the Option Plan shall be determined by the Compensation Committee of the Board but shall not exceed 10 years from the grant date. Vesting conditions of any stock options granted under the Stock Option Plan shall be determined by the Board at the time of grant.

## Stock Option Activity

#### For the nine months ended September 30, 2021

- On September 17, 2021, the Company issued 2,050,000 stock options with an exercise price of \$0.47, expiring on September 17, 2031 and vest as follows: 10% on grant date, 30% 6 months from grant date, 30% 12 months from grant date and 30% 18 months from grant date. The grant date fair value of the options was \$860,734 which was determined using the Black-Scholes option pricing model and the following assumptions: estimated volatility of 100%, risk free interest rate of 1.29%, expected life of 10 years, exercise price of \$0.47, a dividend yield of 0%, and a share price of \$0.47. During the nine months ended September 30, 2021, the Company recorded share-based payments of \$119,965 in the statement of loss and comprehensive loss. As of September 30, 2021, 205,000 stock options have fully vested.

#### For the nine months ended September 30, 2020

- There was no stock option activity for the nine months ended September 30, 2020

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 13. Share Capital and Reserves (cont'd)

Stock option activities are summarized in the table below:

	Number of Stock Options	Weighted Average Exercise Price
Balance, December 31, 2020	-	-
Granted	2,050,000	\$0.47
Balance, September 30, 2021	2,050,000	\$0.47

Details of the share options outstanding and exercisable as at September 30, 2021 are as follows:

	Number of Options	Number of Options	
Expiry date	Outstanding	Vested	<b>Exercise Price</b>
September 17, 2031	2,050,000	205,000	\$0.47
Balance, September 30, 2021	2,050,000	205,000	

As of September 30, 2021, the weighted average remaining life for outstanding options was 9.97 years.

#### Warrants

For the nine months ended September 30, 2021

- On September 17, 2021, the Company issued 898,889 finder's warrants with a fair value of \$251,921 estimated using the Black-Scholes pricing model and the following assumptions: estimated volatility of 117.62%, risk free interest rate of 0.46%, expected life of 2 years, exercise price of \$0.47, a dividend yield of 0%, and a share price of \$0.47. Each finders' warrant entitles the holder to purchase one common share at a price of \$0.47 per common share until September 17, 2023.

## For the nine months ended September 30, 2020

- There was no warrant activity for the nine months ended September 30, 2020

Warrant activities are summarized in the table below:

	Number of Warrants	Weighted Average Exercise Price
Balance, December 31, 2020	-	-
Granted	898,889	\$0.47
Balance, September 30, 2021	898,889	\$0.47

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 13. Share Capital and Reserves (cont'd)

Details of the warrants outstanding and exercisable as at September 30, 2021 are as follows:

	Number of	
Expiry date	Warrants	<b>Exercise Price</b>
September 17, 2023	898,889	\$0.47
Balance, September 30, 2021	898,889	

As of September 30, 2021, the weighted average remaining life for outstanding warrants was 1.96 years.

#### 14. Related Party Transactions

#### a) Due to related parties

As at September 30, 2021, included in due from related parties is \$8,665 (December 31, 2020 - \$8,688) due from directors of the Company. The amount is unsecured, non-interest bearing and due on demand.

As at September 30, 2021, included in due from related parties is \$762 (December 31, 2020 - \$Nil) due from directors of the Company. The amount is unsecured, non-interest bearing and due on demand.

As at September 30, 2021, included in prepaids and deposits is \$Nil (December 31, 2020 - \$9,557) for a salary advance paid to a director of the Company. The amount is unsecured, non-interest bearing and due on demand.

As at September 30, 2021, included in accounts payable and accrued liabilities is 4,986 (December 31, 2020 – 41,939) due to a director of the Company. The amount consists of expenses charged to a personal credit card of a director of the Company and is unsecured, non-interest bearing and due on demand.

As at September 30, 2021, included in accounts payable and accrued liabilities is 2,287 (December 31, 2020 – 28,338) due to a company controlled by a director of the Company. The amount consists of accounting and corporate secretarial fees charged and is unsecured, non-interest bearing and due on demand.

As at September 30, 2021, included in accounts payable and accrued liabilities is \$Nil (December 31, 2020 – \$29,150) due to a LLC controlled by a director of the Company. The amount consists of lease payments due for a building previously occupied by the Company and is unsecured, non-interest bearing and due on demand.

As at September 30, 2021, included in accounts payable and accrued liabilities is Nil (December 31, 2020 – 19,115) due to a director of the Company. The amount consists of salary owed and is unsecured, non-interest bearing and due on demand.

As at September 30, 2021, included in accounts payable and accrued liabilities is 171,579 (December 31, 2020 - 19,115) due to the estate of a former officer of the Company. The amount consists of salary owed and is unsecured, non-interest bearing and due on demand.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

### 14. Related Party Transactions (cont'd)

During the nine months September 30, 2021, the Company had outstanding revolving loans from companies controlled by the CEO and director of the Company (see Note 11) and includes interest charged on the promissory note. The loans are unsecured, bear interest at 6% per annum, and are due on demand. The balance payable as of September 30, 2021 was \$5,639 (2020 - \$8,185).

As at September 30, 2021, the Company had an outstanding promissory note of USD \$160,000 with a company controlled by the CEO and director of the Company. The promissory note is unsecured, bears interest at a rate of 10% per annum, and is due on demand. The balance payable as of September 30, 2021 was \$203,353 (December 31, 2020 - \$203,888). Interest of \$15,045 (2020 - 10,983) for the promissory note was charged and included in the accrued liabilities balance. Interest charged on the revolving loan during the nine months ended September 30, 2021 was \$14,811 (2020 -\$Nil).

#### b) Related party transactions

Key management consists of the directors and officers who are responsible for planning, directing, and controlling the activities of the Company. The Company incurred charges with related parties recorded at their exchange amounts as agreed upon by transacting parties as follows:

For the nine months ended September 30,	2021	2020
Salaries and benefits	\$ 691,852	\$ 232,549
Share-based payments	105,775	-
Termination benefits	168,910	-
	\$ 966,537	\$ 232,549

#### Other transactions

During the nine months ended September 30, 2021, the Company settled debt owing to a company controlled by the CFO of \$39,361 in exchange for 997,426 common shares of the Company.

During the nine months ended September 30, 2021, the Company incurred accounting fees and corporate secretary fees of \$92,098 (2020 - \$Nil) to a company controlled by the CFO of the Company.

During the nine months ended September 30, 2021, the Company was charged USD\$11,505 (CAD\$14,395) (2020 – USD\$9,396 or CAD\$12,712) in lease payments for equipment by a company controlled by the CEO and Director.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 15. Supplemental Disclosure with Respect to Cash Flows

Investing and financing activities that do not have a direct impact on cash flows are excluded from the statement of cash flows.

	For the nine months ended		
	Sep	otember 30, 2021	September 30, 2020
Cash paid for interest	\$	151,042	-
Shares issued for reverse takeover		251	-
Lease payments in accrued liabilities		11,756	-
Fair value of shares issued for debt settlement		39,361	-
Fair value of convertible debt converted	\$	1,711,578	-

## 16. Reverse Takeover Transaction of Nepra Foods Inc.

On April 6, 2021, Nepra US entered into a share exchange agreement (the "Share Exchange Agreement") with the Company, whereby the Company will acquire all of the issued and outstanding shares Nepra US from Nepra US's shareholders ("the "Shareholders") in exchange for certain shares in the capital of the Company. Pursuant to the agreement, the Nepra US's shareholders will receive securities of the Company on the following basis:

- (i) U.S. Shareholders will receive 56.5082 common shares of the Company. for each 1 share of Nepra US with respect to 10% of the shares of Nepra US held by each U.S Shareholder and 0.565082 of a Class A common share of the Company for each 1 share of Nepra US with respect to 90% of the shares of Nepra US held by each U.S. Shareholder, and
- Each non-U.S. Shareholder will receive 56.5082 Common Shares of the Company for each 1 share of Nepra US.

On April 15, 2021, the Share Exchange Agreement closed and Nepra US became a wholly-owned subsidiary of the Company. On April 16, 2021, an aggregate of 14,653,108 shares and 273,468 Class A common shares of the Company were issued to the shareholders of Nepra US in exchange for their 743,254 shares in Nepra US.

As a result of the acquisition, Nepra US is deemed to be the acquirer for accounting purposes and therefore the RTO has been accounted for as if Nepra US issued its own shares to acquire the shares of the Company through the issuance of 14,653,108 common shares at an estimated value of \$2.51 per share. As Nepra US is deemed to be the acquirer for accounting purposes, its assets, liabilities and operations will be included in the consolidated financial statements at their historical carrying value. The Company's results of operations have been included from the RTO effective date. Nepra US's operations are considered to be a continuance of the business and operations.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 16. Reverse Takeover Transaction of Nepra Foods Inc. (cont'd)

At the time of the RTO, the Company did not constitute a business as defined under IFRS 3 - Business *Combinations*; therefore, the RTO is accounted for under IFRS 2 - Share-based payments, where the difference between the consideration given to acquire the Company and the net asset value of the Company is recorded as a transaction cost to profit and loss and is calculated as follows:

Consideration:	
Fair value of shares retained by former Nepra shareholders (100 shares)	\$ 251
Fair value of net assets assumed:	
Cash	251
Accounts payable and accrued liabilities	(51,907)
Net identifiable assets acquired	(51,656)
Transaction expense	\$ 51,907

#### 17. Capital Risk Management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue its operations as well as to ensure that the Company is able to meet its financial obligations as they become due. The capital structure consists of owners' equity comprising of loans payable, promissory note payable, convertible notes, shareholders' capital, capital reserve, and retained earnings (deficit).

The basis for the Company's capital structure is dependent on the Company's expected business growth and changes in business environment. To maintain or adjust the capital structure, the Company may issue new shares through private placement, incur debt, or return capital to shareholders.

The Company believes it will be able to raise capital as required in the long term but recognizes there will be risks involved that may be beyond its control. There are no external restrictions on the management of capital.

The Company does not presently utilize any quantitative measures to monitor its capital, but rather relies on the expertise of the Company's management to sustain the future development of the business. Management reviews its capital management approach on an ongoing basis and believes that this approach is reasonable. There was no change to the Company's approach to capital management during the nine months ended September 30, 2021.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 18. Financial Instruments and Risk Management

The Company is exposed, through its operations, to the following financial risks:

- a) Market Risk
- b) Credit Risk
- c) Liquidity Risk

In common with all other businesses, the Company is exposed to risks that arise from its use of financial instruments. This note describes the Company's objectives, policies, and processes for managing those risks and the methods used to measure them. Further quantitative information in respect of these risks is presented throughout these financial statements.

## General Objectives, Policies, and Processes:

The directors and officers have overall responsibility for the determination of the Company's risk management objectives and policies and, whilst retaining ultimate responsibility for them, it has delegated the authority for designing and operating processes that ensure the effective implementation of the objectives and policies to the Company's finance function. The directors and officers review the effectiveness of the processes put in place and the appropriateness of the objectives and policies it sets.

There have been no substantive changes in the Company's exposure to financial instrument risks, its objectives, polices and processes for managing those risks or the methods used to measure them from previous reported periods unless otherwise stated in the note.

The overall objective of the directors and officers is to set policies that seek to reduce risk as far as possible without unduly affecting the Company's competitiveness and flexibility. Further details regarding these policies are set out below.

#### a) Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as foreign currency exchange, interest rates, and equity price risk.

## (i) Foreign Currency Risk:

The Company's functional currency is the United States dollar and major purchases and sales are transacted in United States dollars. As a result, management believes the Company's exposure to foreign currency risk is minimal.

#### (ii) Interest Rate Risk:

Interest rate risk is the risk that future cash flows will fluctuate because of changes in market interest rates. The interest earned on cash is insignificant, and the Company does not rely on interest to fund its operations. The Company's outstanding promissory note, loans payable, and convertible notes bear interest at fixed rates. As a result, at September 30, 2021, management believes that the Company is not exposed to any significant interest rate risk.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 18. Financial Instruments and Risk Management (cont'd)

## (iii) Equity Price Risk

The Company is exposed to price risk with respect to equity prices. Equity price risk is defined as the potential adverse impacts on the Company's earnings due to movements in individual equities or the general movements in the level of the stock market. The Company's common shares are not yet publicly traded, and the Company does not hold equity investments in other entities. As a result, the Company is not at a significant risk to fluctuating equity prices.

## b) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

The Company's cash, due from related party and accounts receivables are exposed to credit risk. The Company limits its exposure to credit loss on cash by placing its cash with a high-quality financial institution. The Company has concentrations of credit risk with respect to accounts receivable as large amounts of its accounts receivable are concentrated amongst a small number of customers. The Company performs credit evaluations of its customers but generally does not require collateral to support accounts receivable. The Company has certain amounts of aged receivables that are not deemed impaired as follows:

	Septem	nber 30, 2021	Decen	nber 31, 2020
1-60 days	\$	443,282	\$	96,343
61 - 90 days (past due)		5,911		34,289
Over 90 days (past due)		27,721		14,239
Provision for expected credit losses		(18,842)		(2,010)
Total	\$	458,072	\$	142,861

The Company is exposed to increased credit risk due to major customers that comprise 10% or more of revenue. For the nine months ended September 30, 2021 and 2020, the following revenue was recorded from major customers:

Amount of revenue from major customers	Septem	ber 30, 2021	September 30, 2020		
Customer A	\$	1,593,272	\$	402,819	
Customer B	\$	1,484,500	\$	411,883	
Customer C	\$	-	\$	724,297	

Due from related party consists of advances made to a director of the Company and is believed to be credit worthy.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

## 18. Financial Instruments and Risk Management (cont'd)

#### c) Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. Historically, the Company's sources of funding has been loans from a company controlled by the CEO and director, secured government loans, a secured equipment loan, convertible notes, and the from shares issued in the initial public offering. The Company's access to financing is uncertain. There can be no assurance of continued access to significant debt or equity funding.

	Within one year	Between one and five years	More than five years
Accounts payable and accrued			
liabilities	\$ 1,060,845	\$ -	\$ -
Loans payable	15,154	183,958	-
Lease liability	345,004	1,616,886	2,184,314
Promissory note payable	203,353	-	-
Convertible notes	271,480	-	-
	\$ 1,895,836	\$ 1,800,844	\$ 2,184,314

#### d) Basis of Fair Value

		September		December	
	Level	30, 2021		31, 2020	
FINANCIAL ASSETS					
FVTPL					
Cash	1	\$ 4,279,483	\$	492,976	
Other assets, at amortized cost					
Accounts receivable		519,848		142,861	
Long-term deposit		105,046		148,340	
Due from related party		9,427		8,689	
Total financial assets		\$ 4,913,804	\$	792,866	
FINANCIAL LIABILITIES					
FVTPL					
Convertible notes	3	456,083		844,632	
Other liabilities, at amortized cost					
Accounts payable and accrued liabilities		1,060,845		525,596	
Loans payable		199,112		211,826	
Lease liability		2,570,513		26,641	
Promissory note payable		203,353		203,888	
Total financial liabilities		\$ 4,489,906	\$	1,812,583	

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

#### 18. Financial Instruments and Risk Management (cont'd)

Financial instruments that are measured subsequent to initial recognition at fair value are grouped in Levels 1 to 3 based on the degree to which the fair value is observable:

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs)

The Company uses judgment to select the methods used to make certain assumptions and in performing the fair value calculations in order to determine (a) the values attributed to each component of a transaction at the time of their issuance; (b) the fair value measurements for certain instruments that require subsequent measurement at fair value on a recurring basis; and (c) for disclosing the fair value of financial instruments subsequently carried at amortized cost. These valuation estimates could be significantly different because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market.

The carrying value of the Company's financial instruments approximate their fair values due to their shortterm maturities. Cash is measured at fair value on a recurring basis.

The Company derived the fair value of the Series I and Series II convertible debentures by comparing them to the estimated fair value of Series III tranche and the future discounted cashflows using the effective interest rate of the Series III tranche. A 10% increase in the effective interest rate would result in an increase in the fair value of the convertible debentures of \$48,090. A 10% decrease in the effective interest rate would result in a decrease in the fair value of \$48,090.

The Company derived the fair value of the Series III convertible notes based on the estimated fair value of their conversion feature using the Black Scholes pricing model.

#### **19. Subsequent Events**

- a) On October 1, 2021, the Company granted 300,000 restricted share units to an officer of the Company expiring on September 30, 2024 and vest as follows: 25% 6 months from grant date, 25% 12 months from grant date, 25% 18 months from grant date and 25% 24 months from grant date.
- b) On October 14, 2021, Series III convertible notes with total principal and interest of \$87,200 were converted into 185,531 common shares at a price of \$0.47 per share.
- c) On October 15, 2021, the Company issued 400,000 common shares to a third party as consideration for marketing consulting services.

Notes to the Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in Canadian Dollars) (Unaudited)

- d) On November 9, 2021, Series III convertible notes with total principal and interest of \$163,499 were converted into 347,871 common shares at a price of \$0.47 per share.
- e) On November 10, 2021, the Company issued 19,500 common shares at a price of \$0.47 per share pursuant to the conversion of finder's warrants for gross proceeds of \$9,165.
- f) On January 1, 2022, the Company granted 170,000 restricted share units to certain employees of the Company which vest as follows: 25% immediately, 25% on April 1, 2022, 25% on July 1, 2022 and 25% on October 1, 2022.
- g) On January 1, 2022, the Company granted 100,000 restricted share units and 100,000 employee stock options to an employee of the Company. The restricted share units vest as follows: 25% on April 1, 2022, 25% on October 1, 2022 and 25% on January 1, 2023. The stock options vest as follows: 12.5% immediately, 12.5% on April 1, 2022, 12.5% n July 1, 2022, 12.5% on October 1, 2022, 12.5% on January 1, 2023, 12.5% on April 1, 2023, 12.5% on July 1, 2023 and 12.5% on October 1, 2023.
- h) On January 11, 2022, the Company entered into a 24 month lease agreement with a total cost of \$1,200,000.
- i) On January 24, 2022, the Company issued 42,500 shares upon vesting of restricted share units granted on January 1, 2022
- j) On January 25, 2022, Series III convertible notes with total principal and interest of \$20,648 were converted into 43,932 common shares at a price of \$0.47 per share

## 20. Restatement of Financial Statements

The Condensed Consolidated Statement of Cashflow and Note 15 have been amended and restated to correct the presentation of lease payments and cash interest paid. Cash outflow of \$115,342 for cash interest paid was reclassified out of financing activities in the Condensed Consolidated Statement of Cashflow and into operating activities. As a result of this reclassification, the interest adjustment to net income under the operating activities section of the Condensed Consolidated Statement of Cashflow decreased by \$115,342 and cash interest paid disclosed in Note 15 increased by \$115,342. Note 18 has been amended and restated to disclose the contractual payments of the Company's convertible notes and lease liability. Note 19 has been updated for additional subsequent events to the filing date hereof. The effect of the Amendments does not impact the Company's ongoing operations or cash position.

In addition to the above noted corrections, other financial statement disclosures have been amended as a result of the auditors' review of these condensed interim financial statements.